163 related articles for article (PubMed ID: 36261374)
1. A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma.
Sato K; Imamura H; Watahiki Y; Hazama H; Hashimoto T; Mukae S; Ohhira H
Intern Med; 2023 Jun; 62(11):1611-1615. PubMed ID: 36261374
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
3. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2019 Feb; 58(3):375-380. PubMed ID: 30210131
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
10. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
11. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate.
Yamauchi R; Takeyama Y; Takata K; Fukunaga A; Sakurai K; Tanaka T; Fukuda H; Fukuda S; Kunimoto H; Umeda K; Morihara D; Yokoyama K; Irie M; Shakado S; Sakisaka S; Hirai F
Intern Med; 2020 May; 59(9):1163-1166. PubMed ID: 31956202
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
Liu WP; Wang XP; Zheng W; Ping LY; Zhang C; Wang GQ; Song YQ; Zhu J
Leuk Lymphoma; 2016; 57(6):1355-62. PubMed ID: 26727044
[TBL] [Abstract][Full Text] [Related]
14. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
[TBL] [Abstract][Full Text] [Related]
15. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
Lu S; Xu Y; Mu Q; Cao L; Chen J; Zhu Z; Lou Y; Meng H; Qian W; Tong H; Mai W; Huang J; Yu W; Zhao X; Jin J
Leuk Lymphoma; 2015 Apr; 56(4):1027-32. PubMed ID: 25065698
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
17. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
20. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report.
Ciccullo A; Ponziani FR; Maiolo E; Pallavicini F; Pompili M
Infection; 2019 Apr; 47(2):313-316. PubMed ID: 30368733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
